AKTSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Aktis Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$15.11+0.05 (+0.33%)
Close on Oct 19, 2026
- Market cap
- $835.58M
- P/E (TTM)
- –
- Dividend yield
- –
SEC filings
8 of Aktis Oncology's most recent filings on SEC EDGAR
| Document | Form | Period | Filed | Source |
|---|---|---|---|---|
| Quarterly report | 10-Q | Jun 30, 2026 | Aug 13, 2026 | SEC EDGAR |
| Current report | 8-K | Aug 13, 2026 | Aug 13, 2026 | SEC EDGAR |
| Quarterly report | 10-Q | Mar 31, 2026 | May 11, 2026 | SEC EDGAR |
| Current report | 8-K | May 11, 2026 | May 11, 2026 | SEC EDGAR |
| Current report | 8-K | Apr 15, 2026 | Apr 16, 2026 | SEC EDGAR |
| Current report | 8-K | Mar 30, 2026 | Mar 30, 2026 | SEC EDGAR |
| Annual report | 10-K | Dec 31, 2025 | Mar 30, 2026 | SEC EDGAR |
| Current report | 8-K | Jan 12, 2026 | Jan 12, 2026 | SEC EDGAR |